JP2023517536A - 炎症状態に使用するための化合物 - Google Patents

炎症状態に使用するための化合物 Download PDF

Info

Publication number
JP2023517536A
JP2023517536A JP2022552946A JP2022552946A JP2023517536A JP 2023517536 A JP2023517536 A JP 2023517536A JP 2022552946 A JP2022552946 A JP 2022552946A JP 2022552946 A JP2022552946 A JP 2022552946A JP 2023517536 A JP2023517536 A JP 2023517536A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
day
compound
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517536A5 (https=
Inventor
パブロ・アヴィレス・マリン
アレハンドロ・ロサーダ・ゴンザレス
ホセ・マリア・フェルナンデス・ソウサ－ファロ
サルヴァドール・フディオ・ムニョス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of JP2023517536A publication Critical patent/JP2023517536A/ja
Publication of JP2023517536A5 publication Critical patent/JP2023517536A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022552946A 2020-03-02 2021-03-02 炎症状態に使用するための化合物 Pending JP2023517536A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP20382152.5 2020-03-02
EP20382152 2020-03-02
EP20382192.1 2020-03-13
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382266.3 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382816.5 2020-09-16
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25
PCT/EP2021/055187 WO2021175857A1 (en) 2020-03-02 2021-03-02 Compounds for use in inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2023517536A true JP2023517536A (ja) 2023-04-26
JP2023517536A5 JP2023517536A5 (https=) 2024-03-12

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552946A Pending JP2023517536A (ja) 2020-03-02 2021-03-02 炎症状態に使用するための化合物
JP2022552937A Pending JP2023517535A (ja) 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022552937A Pending JP2023517535A (ja) 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物

Country Status (17)

Country Link
US (2) US20230159594A1 (https=)
EP (2) EP4114433A2 (https=)
JP (2) JP2023517536A (https=)
KR (2) KR20220151643A (https=)
CN (2) CN115461067A (https=)
AU (2) AU2021232535A1 (https=)
BR (2) BR112022016604A2 (https=)
CA (2) CA3169540A1 (https=)
CL (2) CL2022002396A1 (https=)
CO (2) CO2022014093A2 (https=)
IL (2) IL296069A (https=)
MX (2) MX2022010926A (https=)
PE (2) PE20230606A1 (https=)
PY (2) PY2117301A (https=)
TW (2) TWI908772B (https=)
UY (2) UY39109A (https=)
WO (2) WO2021175831A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517295A (ja) * 2020-03-02 2023-04-25 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置に使用する化合物
JP2023517535A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ ウイルス感染に使用するための化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502441A (ja) * 1989-09-29 1993-04-28 ファーマ　マー，ソシエダッド　アノニマ デヒドロジデムニンｂ
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
JP2002511406A (ja) * 1998-04-14 2002-04-16 ヨマー、ハッサン 感染症の治療および予防処置のための有機リン化合物の使用
JP2004517835A (ja) * 2000-12-07 2004-06-17 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
JP2006518769A (ja) * 2003-02-21 2006-08-17 サン・ファーマシューティカル・インダストリーズ・リミテッド 安定な眼科用組成物
JP2013514382A (ja) * 2009-12-15 2013-04-25 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
JP2016539345A (ja) * 2013-09-17 2016-12-15 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ 結核のバイオマーカー
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2018232383A1 (en) * 2017-06-16 2018-12-20 Vanderbilt University Methods and compositions for treating microbial inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502441A (ja) * 1989-09-29 1993-04-28 ファーマ　マー，ソシエダッド　アノニマ デヒドロジデムニンｂ
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
JP2002511406A (ja) * 1998-04-14 2002-04-16 ヨマー、ハッサン 感染症の治療および予防処置のための有機リン化合物の使用
JP2004517835A (ja) * 2000-12-07 2004-06-17 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
JP2006518769A (ja) * 2003-02-21 2006-08-17 サン・ファーマシューティカル・インダストリーズ・リミテッド 安定な眼科用組成物
JP2013514382A (ja) * 2009-12-15 2013-04-25 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
JP2016539345A (ja) * 2013-09-17 2016-12-15 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ 結核のバイオマーカー
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2018232383A1 (en) * 2017-06-16 2018-12-20 Vanderbilt University Methods and compositions for treating microbial inflammation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, JPN6025016008, 2012, pages 709 - 712, ISSN: 0005838762 *
BLOOD, vol. 112 (11): 3700, JPN6025002650, 2008, ISSN: 0005838760 *
DRUG DISCOVERY TODAY, vol. 19, no. 5, JPN6025016010, 2014, pages 645 - 653, ISSN: 0005838764 *
INTERNATIONAL IMMUNOLOGY, vol. 30, no. 2, JPN6026014475, 2018, pages 43 - 51, ISSN: 0005838766 *
MARINE DRUGS, vol. 11, JPN6025016011, 2013, pages 4478 - 4486, ISSN: 0005711722 *
SCIENCE, vol. 212, JPN6025002649, 1981, pages 933 - 935, ISSN: 0005838761 *
STUDIES IN NATURAL PRODUCTS CHEMISTRY, vol. 62, JPN6025016009, 2019, pages 455 - 481, ISSN: 0005838763 *
ウイルス, vol. 54, no. 2, JPN6025043161, 2004, pages 145 - 152, ISSN: 0005838765 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517295A (ja) * 2020-03-02 2023-04-25 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置に使用する化合物
JP2023517535A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ ウイルス感染に使用するための化合物

Also Published As

Publication number Publication date
WO2021175857A1 (en) 2021-09-10
IL296068A (en) 2022-11-01
PE20230412A1 (es) 2023-03-07
PY2117301A (es) 2022-08-09
PY2117308A (es) 2022-08-09
TWI908772B (zh) 2025-12-21
TW202144381A (zh) 2021-12-01
CN115461067A (zh) 2022-12-09
KR20220150350A (ko) 2022-11-10
JP2023517535A (ja) 2023-04-26
UY39109A (es) 2021-09-30
CA3169540A1 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
UY39110A (es) 2021-09-30
AU2021232535A1 (en) 2022-10-06
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
MX2022010921A (es) 2022-09-29
KR20220151643A (ko) 2022-11-15
AU2021231197A1 (en) 2022-10-06
EP4114435A1 (en) 2023-01-11
IL296069A (en) 2022-11-01
CO2022014093A2 (es) 2022-11-18
TW202146038A (zh) 2021-12-16
EP4114433A2 (en) 2023-01-11
US20230295236A1 (en) 2023-09-21
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
CA3169544A1 (en) 2021-09-10
WO2021175831A2 (en) 2021-09-10
CN115666616A (zh) 2023-01-31
CL2022002396A1 (es) 2023-06-30
CO2022014031A2 (es) 2022-10-21
MX2022010926A (es) 2022-09-29
BR112022016675A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
ŞİMŞEK YAVUZ et al. An update of anti-viral treatment of COVID-19.
Kaddoura et al. COVID-19 therapeutic options under investigation
JP2023517536A (ja) 炎症状態に使用するための化合物
KR20200131784A (ko) 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
EP3952841A1 (en) Drug adsorbed highly porous activated carbon for enhanced drug delivery
Yavuz et al. An update of anti-viral treatment of COVID-19
JP2014532657A (ja) Ｃ型肝炎ウイルスを処置するための方法および組成物
WO2012136851A1 (en) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
JP2023521403A (ja) コロナウイルス病２０１９（ｃｏｖｉｄ－１９）の治療のためのマシチニブの使用
US10765664B2 (en) Treatment of infectious diseases
CN115243703A (zh) 用于组合治疗冠状病毒的pld
WO2019141263A1 (zh) 一种广谱抗肠道病毒的多肽及其应用
JP2023517295A (ja) コロナウイルス感染の処置に使用する化合物
Gazina et al. Viral targets of acylguanidines
EA050436B1 (ru) Соединения для применения при воспалительных состояниях
EP4135744A1 (en) Prevention and treatment of viral infection-induced organ failure
EA050340B1 (ru) Соединения для применения в лечении коронавирусной инфекции
Moshiri Mechanical Force Sensing Drives Extrusion of Enterovirus-A71-Infected Cells from Colonic Epithelial Organoids
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20221201

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20220902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414